ArticleMolecules (Basel, Switzerland)2016
Inhalable Antitubercular Therapy Mediated by Locust Bean Gum Microparticles.
Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 48 citations in OpenAlex.
- Extraction, Physicochemical Properties, and Biomedical Applications of Locust Bean Gum: A Comprehensive Review.Mini reviews in medicinal chemistry · 2025Review
- Rifabutin loaded inhalable β-glucan microparticle based drug delivery system for pulmonary TB.Scientific reports · 2024Article
- Inhalation Dosage Forms: A Focus on Dry Powder Inhalers and Their Advancements.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges.Microorganisms · 2023Review
- Recent Advances in Pharmaceutical Approaches of Antimicrobial Agents for Selective Delivery in Various Administration Routes.Antibiotics (Basel, Switzerland) · 2023Review
- Polysaccharide-Based Carriers for Pulmonary Insulin Delivery: The Potential of Coffee as an Unconventional Source.Pharmaceutics · 2023Article
- Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs.Molecules (Basel, Switzerland) · 2021Article
- Host Bioenergetic Parameters Reveal Cytotoxicity of Antituberculosis Drugs Undetected Using Conventional Viability Assays.Antimicrobial agents and chemotherapy · 2021Article
- Microencapsulated Chitosan-Based Nanocapsules: A New Platform for Pulmonary Gene Delivery.Pharmaceutics · 2021Article
- Carrageenan from red algae: an application in the development of inhalable tuberculosis therapy targeting the macrophages.Drug delivery and translational research · 2020Article
- Inhalable Spray-Dried Chondroitin Sulphate Microparticles: Effect of Different Solvents on Particle Properties and Drug Activity.Polymers · 2020Article
- Multifunctional Nanocarriers for Lung Drug Delivery.Nanomaterials (Basel, Switzerland) · 2020Review
- Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery.Pharmaceutics · 2019Article
- Inhalable Fucoidan Microparticles Combining Two Antitubercular Drugs with Potential Application in Pulmonary Tuberculosis Therapy.Polymers · 2018Article
- Wet heat energy for reaction of 2-hydroxy-1,2,3-propanetricarboxylic acid with caruba and applications for pharmaceutical dosage forms.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis remains a major global health problem and alternative therapeutic approaches are needed. Considering the high prevalence of lung tuberculosis (80% of cases), the pulmonary delivery of antitubercular drugs in a carrier system capable of reaching the alveoli, being recognised and phagocytosed by alveolar macrophages (mycobacterium hosts), would be a significant improvement to current oral drug regimens. Locust bean gum (LBG) is a polysaccharide composed of galactose and mannose residues, which may favour specific recognition by macrophages and potentiate phagocytosis. LBG microparticles produced by spray-drying are reported herein for the first time, incorporating either isoniazid or rifabutin, first-line antitubercular drugs (association efficiencies >82%). Microparticles have adequate theoretical properties for deep lung delivery (aerodynamic diameters between 1.15 and 1.67 μm). The cytotoxic evaluation in lung epithelial cells (A549 cells) and macrophages (THP-1 cells) revealed a toxic effect from rifabutin-loaded microparticles at the highest concentrations, but we may consider that these were very high comparing with in vivo conditions. LBG microparticles further evidenced strong ability to be captured by macrophages (percentage of phagocytosis >94%). Overall, the obtained data indicated the potential of the proposed system for tuberculosis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.